Segal NH, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, Hollebecque A, Reilley MJ, Elez E, Cosaert J, Cain J, Soo-Hoo Y, Hewson N, Cooper ZA, Kumar R, Tabernero J. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. British Journal of Cancer. 2024;:10.1038/s41416-024-02796-3
Taieb J, Basile D, Seligmann J, Argiles G, André T, Gallois C, Goldberg RM, Yothers G, Sobrero A, Meyerhardt JA, Souglakos J, Labianca R, Iveson T, Church DN, Arnold D, Tie J, Gill S, Laurent-Puig P, Yoshino T, Lonardi S, Shi Q. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts. European Journal of Cancer. 2024;206:10.1016/j.ejca.2024.114118
Jalali A, Smith S, Kim G, Wong H, Lee M, Yeung J, Loft M, Wong R, Shapiro JD, Kosmider S, Tie J, Ananda S, Ma B, Burge M, Jennens R, Lee B, Johns J, Lim L, Dean A, Nott L, Gibbs P. Early onset metastatic colorectal cancer in Australia. Cancer Treatment and Research Communications. 2024;40:10.1016/j.ctarc.2024.100827
Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, Lee M, Harris M, McLachlan S-A, Ananda S, UNDERHILL CR, Papadopoulos N, Tomasetti C, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.Journal of Clinical Oncology. 2024;42(16_suppl):10.1200/jco.2024.42.16_suppl.108
Wong V, Loft M, Kosmider S, Wong R, Shapiro JD, Hong W, Jennens R, Tie J, Caird S, Steel SA, Lee B, Nott LM, Khattak A, Lim SH-S, Chong G, Hayes TM, Underhill CR, McLachlan S-A, Rainey N, Gibbs P. Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer.Journal of Clinical Oncology. 2024;42(16_suppl):10.1200/jco.2024.42.16_suppl.e15569
Basile D, Seligmann J, Martinez GA, André T, Gallois C, Goldberg RM, Yothers G, Sobrero A, Meyerhardt J, Souglakos I, Labianca R, Church DN, Arnold D, Tie J, Gill S, Laurent-Puig P, Yoshino T, Lonardi S, Shi Q, Taieb J. 24P Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts. Annals of Oncology. 2024;35:10.1016/j.annonc.2024.05.035
Tie J, Wang Y, Cohen JD, Shapiro JD, Wong R, Aghmesheh M, Kiberu AD, Francesconi A, Burge ME, Roy AC, Dobbyn L, Ptak J, Silliman N, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial.Journal of Clinical Oncology. 2024;42(16_suppl):10.1200/jco.2024.42.16_suppl.107
Li Y, Heer AK, Sloane HS, Edelstein DL, Tie J, Gibbs P, Barzi A. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans. JAMA Health Forum. 2024;5(5):10.1001/jamahealthforum.2024.1270
Piercey O, Tie J, Hollande F, Wong H-L, Mariadason J, Desai J. BRAFV600E -Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities. Clinical Colorectal Cancer. 2024;:10.1016/j.clcc.2024.04.004
Piercey O, Wong H-L, Leung C, To YH, Heong V, Lee M, Tie J, Steel M, Yeung JM, McCormick J, Gibbs P, Wong R. Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence. Clinical Colorectal Cancer. 2024;23(1):10.1016/j.clcc.2024.01.001
